Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Takeda will seek an external partner to leverage its cell therapy platform technologies
The new site enables end-to-end production of viral vector gene therapies
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated
